Pfizer & Bristol-Myers Squibb’s Eliquis Successful, Protalix Treats 1st Fabry Patient: Healthcare Biz Recap

A study published in Saturday’s New England Journal of Medicine showed that Pfizer (NYSE:PFE) and Bristol-Myers Squibb Company’s (NYSE:BMY) experimental drug Eliquis both prevented blood clots in the legs and lungs and kept them from recurring. Patients who taking the medication were 81 percent less likely to have symptoms of a clot or die than those who got a placebo, and if Eliquis should gain approval, it could generate sales of $4.18 billion for Bristol-Myers by 2018, according to Bloomberg. Meanwhile, two new rival therapies, Xarelto by Johnson & Johnson (NYSE:JNJ) and Bayer (BAYZF.PK) and Pradaxa by Boehringer Ingelheim, are okayed for use against types of deep vein clots.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

In a Monday release, Protalix BioTherapeutics (AMEX:PLX) said that the first patient has been treated in its phase I/II clinical trial of Fabry patients with PRX-102, marking the firm’s proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease.

Don’t Miss: Will “Pay for Delay” Ruling Cost Drug Companies?